Stereotactic body radiotherapy

• Published in: BMC cancer 2020-05, Vol.20 (1)
• Main Authors: Kessel, Kerstin A, Grosser, Rebekka C. E, Kraus, Kim Melanie, Hoffmann, Hans, Oechsner, Markus, Combs, Stephanie E
• Format: Article
• Language: English
• Subjects: Analysis; Cancer metastasis; Care and treatment; Lung diseases; Medical research; Patient outcomes; Prognosis; Radiotherapy
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-020-6635-8

The present study aims to evaluate long-term side-effects and outcomes and confirm prognostic factors after stereotactic body radiotherapy (SBRT) of pulmonary lesions. This is the first work that combines the investigated data from patient charts and patient-reported outcome (PRO) up to 14 years after therapy. We analyzed 219 patients and 316 lung metastases treated between 2004 and 2019. The pulmonary lesions received a median dose and dose per fraction of 35 Gy (range: 14-60.5 Gy) and 8 Gy (range: 3-20 Gy) to the surrounding isodose. During the last 1.5 years of monitoring, we added PRO assessment to our follow-up routine. We sent an invitation to a web-based survey questionnaire to all living patients whose last visit was more than 6 months ago. Median OS was 27.6 months. Univariate analysis showed a significant influence on OS for KPS [greater than or equai to]90%, small gross tumor volume (GTV) and planning target volume (PTV), the absence of external metastases, [less than or equai to]3 pulmonary metastases, and controlled primary tumor. The number of pulmonary metastases and age influenced local control (LC) significantly. We could confirm excellent local control and low toxicity rates. PROs improve and complement follow-up care. They are an essential measure in addition to the physician-reported outcomes. Future research must be conducted regarding the correct interpretation of PRO data.